Journal of Carcinogenesis & Mutagenesis

Challenges in the Diagnosis and Treatment of Pancreatic Adenocarcinoma

Neha Kapoor^* Department of Oncology, Institute of Medical Sciences, Mumbai, India
^*Correspondence: Neha Kapoor, Department of Oncology, Institute of Medical Sciences, Mumbai, India, Email:

Received: 30-Sep-2025, Manuscript No. JCM-25-30868; Editor assigned: 02-Oct-2025, Pre QC No. JCM-25-30868 (PQ); Reviewed: 16-Oct-2025, QC No. JCM-25-30868; Revised: 23-Dec-2025, Manuscript No. JCM-25-30868 (R); Published: 30-Oct-2025, DOI: 10.35248/2157-2518.25.16.487

Description

Pancreatic adenocarcinoma represents one of the most aggressive and lethal forms of cancer, accounting for the majority of pancreatic malignancies. It originates from the exocrine component of the pancreas, specifically the ductal epithelial cells and is characterized by rapid progression, early metastasis and poor overall prognosis. Despite advances in diagnostic techniques and therapeutic strategies, survival rates remain low, largely due to late detection, tumor heterogeneity and resistance to conventional treatments. Understanding the molecular, cellular and clinical aspects of pancreatic adenocarcinoma is important for developing effective interventions and improving patient outcomes.

The pathogenesis of pancreatic adenocarcinoma is complex and involves a combination of genetic, epigenetic and environmental factors. Genetic mutations are central to disease development, with the oncogene being the most frequently altered, present in over 90 percent of cases. Activating mutations in drive uncontrolled proliferation and contribute to the initiation of neoplastic lesions known as pancreatic intraepithelial neoplasias. These genetic alterations lead to deregulation of cell cycle control, evasion of apoptosis and increased potential for invasion and metastasis. Epigenetic modifications, including methylation and histone modification, also play a role by silencing tumor suppressor genes and activating oncogenic pathways.

The tumor microenvironment in pancreatic adenocarcinoma is another critical factor influencing disease progression. The desmoplastic stroma, composed of fibroblasts, extracellular matrix components and immune cells, creates a dense barrier that impedes drug delivery and contributes to chemo resistance. Cancer-associated fibroblasts secrete growth factors and cytokines that support tumor survival and invasion. In parallel, immunosuppressive cells, including regulatory T cells and myeloid-derived suppressor cells, inhibit anti-tumor immune responses, allowing cancer cells to evade immune surveillance. This complex interplay between cancer cells and the surrounding stroma highlights the importance of targeting both the tumor and its microenvironment in therapeutic strategies.

Clinically, pancreatic adenocarcinoma is challenging to detect in its early stages because symptoms are often nonspecific. Patients may present with abdominal pain, jaundice, weight loss, or newonset diabetes, but these signs typically appear after the tumor has grown or metastasized. Imaging techniques such as computed tomography, magnetic resonance imaging and endoscopic ultrasound are essential for diagnosis and staging, while biopsy and histopathological examination confirm the presence of adenocarcinoma. Biomarkers such as carbohydrate antigen 19-9 can aid in monitoring disease progression, but they lack sufficient sensitivity and specificity for early detection. Consequently, a significant proportion of patients are diagnosed at advanced stages, limiting the effectiveness of curative interventions.

Surgical resection remains the only potentially curative treatment for pancreatic adenocarcinoma, with procedures such as pancreaticoduodenectomy offering the best chance for longterm survival. However, only a minority of patients are eligible due to the advanced stage at diagnosis or the presence of distant metastases. For unrespectable tumours, chemotherapy and radiotherapy are employed to control disease progression and relieve symptoms. Regimens based on gemcitabine or combination therapies have improved survival modestly but are often associated with significant toxicity. Recent advances in molecular profiling have led to the exploration of targeted therapies and immunotherapies. Inhibitors targeting specific mutations or signalling pathways, as well as immune checkpoint inhibitors, hold promise, but their efficacy in pancreatic adenocarcinoma has been limited, largely due to the immunosuppressive microenvironment.

Research continues to focus on identifying novel biomarkers for early detection, understanding mechanisms of drug resistance and developing personalized therapeutic approaches. Liquid biopsy techniques, including circulating tumor analysis, offer potential for non-invasive monitoring and early diagnosis. Strategies to remodel the tumor stroma or enhance immune infiltration are also under investigation, aiming to overcome the barriers posed by the pancreatic tumor microenvironment. Multidisciplinary approaches integrating surgery, chemotherapy, radiotherapy and targeted therapies are increasingly recognized as essential for optimizing patient outcomes.

In conclusion, pancreatic adenocarcinoma is a highly aggressive malignancy with complex molecular and clinical characteristics that contribute to its poor prognosis. Genetic mutations, epigenetic changes and interactions with the tumor microenvironment drive disease initiation, progression and resistance to therapy. Early detection remains a major challenge due to nonspecific symptoms and the lack of reliable biomarkers, resulting in late-stage diagnosis in most patients. While surgical resection offers the only curative option, systemic therapies provide limited survival benefits, highlighting the urgent need for novel treatment strategies. Advances in molecular biology, tumor microenvironment research and personalized medicine provide hope for improved diagnostic and therapeutic approaches.